ONCY secures U.S. patent for pelareorep manufacturing through 2044

Oncolytics Biotech Inc. (NASDAQ: ONCY) announced that the U.S. Patent and Trademark Office has issued a new patent covering the manufacturing process for its investigational immunotherapy pelareorep, with protection expected to extend through 2044.

The patent covers key aspects of the methods used to produce pelareorep and is intended to protect the company's ability to manufacture the therapy at commercial scale.

The company also noted that a previously filed method-of-use patent application, directed at pelareorep's use as an immunotherapy, remains under review by the USPTO. If issued, that patent is expected to provide protection through 2046.

Oncolytics said it plans to file additional patent applications in 2026 covering additional therapeutic applications, treatment settings, and combination approaches.

"This newly issued patent strengthens our protection around the manufacturing of pelareorep and supports our ability to produce the product at commercial scale," said Jared Kelly, Chief Executive Officer of Oncolytics.

The company's intellectual property strategy targets protection through a combination of manufacturing, method-of-use, formulation, and combination therapy patents across multiple oncology indications.

Pelareorep is an intravenously delivered immunotherapy being studied in combination with chemotherapy and checkpoint inhibitors for metastatic gastrointestinal cancers. It has received Fast Track designation from the FDA for colorectal and pancreatic cancer.

You May Also Be Interested In

• Dexcom wins FDA pediatric clearance for Stelo glucose sensor
• AST SpaceMobile plans August launch of three more BlueBird satellites
• Myriad Genetics board member Skovronsky resigns